Arcutis Gets FDA Review for Zoryve 0.05% Label Expansion (ARQT)

Arcutis gets FDA review for Zoryve 0.05% label expansion (ARQT)

Arcutis Biotherapeutics (ARQT) stock gains as the FDA agrees to review the company's bid to expand the label of its eczema therapy Zoryve 0.05% cream. Read more here.

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

Open the article to view the coverage from Arcutis Biotherapeutics